Our integrated computational-structural-preclinical approach not only establishes HOXC6 as a novel therapeutic target but also pioneers innovative TF-targeting paradigms, potentially ushering in a new era of molecular subtype-directed CRC treatment. This evidence concerns the gene TF and colorectal carcinoma.